Wegovy(TM) Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity
Bagsværd, Denmark (ots/PRNewswire) - * The STEP 5 trial demonstrated an average weight loss of 15.2% with
Wegovy(TM) at 104-weeks when used with a reduced calorie meal plan
and increased physical activity vs. 2.6% with placebo
* The trial also showed that 77.1% of study participants who received Wegovy(TM) lost at least 5% of their body weight, compared to 34.4% of those who received placebo
Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults!-->…